GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Forward Rate of Return (Yacktman) %

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Sienna Biopharmaceuticals's forward rate of return for was 0.00%.

The historical rank and industry rank for Sienna Biopharmaceuticals's Forward Rate of Return (Yacktman) % or its related term are showing as below:

SNNAQ's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.77
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Sienna Biopharmaceuticals Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Sienna Biopharmaceuticals's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Forward Rate of Return (Yacktman) % Chart

Sienna Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18
Forward Rate of Return (Yacktman) %
- - - -

Sienna Biopharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sienna Biopharmaceuticals's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Sienna Biopharmaceuticals's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sienna Biopharmaceuticals's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sienna Biopharmaceuticals's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Sienna Biopharmaceuticals's Forward Rate of Return (Yacktman) % falls into.



Sienna Biopharmaceuticals Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Sienna Biopharmaceuticals's Forward Rate of Return of Sep. 2019 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.2+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sienna Biopharmaceuticals  (OTCPK:SNNAQ) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Sienna Biopharmaceuticals Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.
Executives
Alexander Azoy officer: Chief Financial Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews officer: General Counsel & Secretary 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield director, officer: President & CEO C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann officer: See Remarks 30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton director
Todd Harris director 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Headlines

From GuruFocus